ABI-009
ABI-009 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
2
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
3 of 6 finished
50.0%
3 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Clinical Trials (7)
ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7